1.	Lindstrom L, Singh Y. History, folklore, traditional and current uses of kava. Kava: From ethnology to pharmacology. 2004:10-28.
2.	Stevinson C, Huntley A, Ernst E. A systematic review of the safety of kava extract in the treatment of anxiety. Drug Saf. 2002;25(4):251-261.
3.	Pittler MH, Edzard E. Kava extract for treating anxiety. Cochrane Database Syst Rev. 2001(4):Cd003383.
4.	Coulter, David, Tamayo, Carmen, Sotheeswaran, Subramaniam, Ulbricht, Catherine & World Health Organization. (‎2007)‎. Assessment of the risk of hepatotoxicity with kava products. World Health Organization. https://apps.who.int/iris/handle/10665/43630.
5.	Soares RB, Dinis-Oliveira RJ, Oliveira NG. An Updated Review on the Psychoactive, Toxic and Anticancer Properties of Kava. J Clin Med. 2022;11(14).
6.	Chua HC, Christensen ET, Hoestgaard-Jensen K, et al. Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism. PloS one. 2016;11(6):e0157700.
7.	Bian T, Corral P, Wang Y, et al. Kava as a Clinical Nutrient: Promises and Challenges. Nutrients. 2020;12(10).
8.	Krum BN, de Freitas CM, Busanello A, Schaffer LF, Fachinetto R. Ex vivo and in vitro inhibitory potential of Kava extract on monoamine oxidase B activity in mice. J Tradit Complement Med. 2021;12(2):115-122.
9.	Organization WH. Kava: a review of the safety of traditional and recreational beverage consumption. In. Vol 1. Rome: Food and Agriculture Organization of the United Nations; 2016:1-35.
10.	Ooi SL, Henderson P, Pak SC. Kava for Generalized Anxiety Disorder: A Review of Current Evidence. J Altern Complement Med. 2018;24(8):770-780.
11.	Sarris J, LaPorte E, Schweitzer I. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust N Z J Psychiatry. 2011;45(1):27-35.
12.	Wang PF, Yang Y, Patel V, Neiner A, Kharasch ED. Natural Products Inhibition of Cytochrome P450 2B6 Activity and Methadone Metabolism. Drug Metab Dispos. 2024;52(3):252-265.
13.	Administration USFaD. Scientific Memorandum: Kava (Piper methysticum). In. College Park, MD: Center for Food Safety and Applied Nutrition; 2020.
14.	Weiss J, Sauer A, Frank A, Unger M. Extracts and kavalactones of Piper methysticum G. Forst (kava-kava) inhibit P-glycoprotein in vitro. Drug Metab Dispos. 2005;33(11):1580-1583.
15.	Pollastri MP, Whitty A, Merrill JC, Tang X, Ashton TD, Amar S. Identification and Characterization of Kava-derived Compounds Mediating TNF-α Suppression. Chemical Biology & Drug Design. 2009;74(2):121-128.
16.	Fragoulis A, Siegl S, Fendt M. Oral administration of methysticin improves cognitive deficits in a mouse model of Alzheimer’s disease. Redox Biology. 2017;12:843-853.
17.	Wruck CJ, Götz ME, Herdegen T, Varoga D, Brandenburg LO, Pufe T. Kavalactones Protect Neural Cells against Amyloid β Peptide-Induced Neurotoxicity via Extracellular Signal-Regulated Kinase 1/2-Dependent Nuclear Factor Erythroid 2-Related Factor 2 Activation. Mol Pharmacol. 2008;73(6):1785-1795.
18.	Dong R, Wang J, Gao X. Yangonin protects against estrogen–induced cholestasis in a farnesoid X receptor-dependent manner. European Journal of Pharmacology. 2019;857(172461).
19.	Chou TW, Feng JH, Huang CC. A Plant Kavalactone Desmethoxyyangonin Prevents Inflammation and Fulminant Hepatitis in Mice. PloS one. 2013;8(10).
20.	Kong Y, Gao X, Wang C. Protective effects of yangonin from an edible botanical Kava against lithocholic acid-induced cholestasis and hepatotoxicity. European Journal of Pharmacology. 2018;824:64-71.
21.	Abu N, Mohamed NE, Tangarajoo N. In vitro Toxicity and in vivo Immunomodulatory Effects of Flavokawain A and Flavokawain B in Balb/C Mice. Natural Product Communications. 2015;10(7).
22.	Huck O, Han X, Mulhall H. Identification of a Kavain Analog with Efficient Anti-inflammatory Effects. Sci Rep. 2019;9(1).
23.	Huck O, You J, Han X, Cai B, Panek J, Amar S. Reduction of Articular and Systemic Inflammation by Kava-241 in a Porphyromonas gingivalis-Induced Arthritis Murine Model. Infection and Immunity. 2018;86(9).
24.	Terazawa R, Akimoto N, Kato T. A kavalactone derivative inhibits lipopolysaccharide-stimulated iNOS induction and NO production through activation of Nrf2 signaling in BV2 microglial cells. Pharmacological Research. 2013;71:34-43.
25.	Wang D, Yang L, Wang J. Behavioral and physiological effects of acute and chronic kava exposure in adult zebrafish. Neurotoxicology and Teratology. 2020;79(106881).
26.	Zhang L, Rowe A, Braet F, Ramzan I. Macrophage depletion ameliorates kavalactone damage in the isolated perfused rat liver. J Toxicol Sci. 2012;37(2):447-453.
27.	Narayanapillai SC, Lin SH, Leitzman P, Upadhyaya P, Baglole CJ, Xing C. Dihydromethysticin (DHM) Blocks Tobacco Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-Induced O(6)-Methylguanine in a Manner Independent of the Aryl Hydrocarbon Receptor (AhR) Pathway in C57BL/6 Female Mice. Chem Res Toxicol. 2016;29(11):1828-1834.
28.	Bian T, Lynch A, Ballas K, et al. AB-free kava enhances resilience against the adverse health effects of tobacco smoke in mice. bioRxiv. 2024.
29.	Yang Y, Wei Z, Teichmann AT. Development of a novel nitric oxide (NO) production inhibitor with potential therapeutic effect on chronic inflammation. European Journal of Medicinal Chemistry. 2020;193(112216).
30.	Kwon D-J, Ju SM, Youn GS, Choi SY, Park J. Suppression of INOS and COX-2 Expression by Flavokawain A via Blockade of NF-ΚB and AP-1 Activation in RAW 264.7 Macrophages. Food and Chemical Toxicology. 2013;58(August):479-486.
31.	Jamieson DD, Duffield PH. The Antinociceptive Actions of Kava Components in Mice. Clinical and Experimental Pharmacology and Physiology. 1990;17(7):495-507.
32.	Magura EI, Kopanitsa MV, Gleitz J, Peters T, Krishtal OA. Kava extract ingredients, (+)-methysticin and (±)-kavain inhibit voltage-operated Na+-channels in rat CA1 hippocampal neurons. Neuroscience. 1997;81(2):345-351.
33.	Gleitz J, Beile A, Peters T. ±)-Kavain inhibits the veratridine- and KCl-induced increase in intracellular Ca2+ and glutamate-release of rat cerebrocortical synaptosomes. Neuropharmacology. 1996;35(2):179-186.
34.	Baum SS, Hill R, Rommelspacher H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 1998;22(7):1105-1120.
35.	Walden J, Wegerer J, Winter U, Berger M, Grunze H. Effects of kawain and dihydromethysticin on field potential changes in the hippocampus. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 1997;21(4):697-706.
36.	Chua HC, Christensen ETH, Hoestgaard-Jensen K. Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism. PloS one. 2016;11(6).
37.	Hegazy NH, Breitinger HG, Breitinger U. Kavalactones from Kava (Piper methysticum) root extract as modulators of recombinant human glycine receptors. Biological Chemistry. 2019;400(9):1205-1215.
38.	Ligresti A, Villano R, Allarà M, Ujváry I, Marzo V. Kavalactones and the endocannabinoid system: The plant-derived yangonin is a novel CB1 receptor ligand. Pharmacological Research. 2012;66(2):163-169.
39.	Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract fromPiper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology. 1994;116(4):469-474.
40.	Yuan CS, Dey L, Wang A, et al. Kavalactones and dihydrokavain modulate GABAergic activity in a rat gastric-brainstem preparation. Planta Med. 2002;68(12):1092-1096.
41.	Petersen GE, Tang Y, Fields C. Chemical and in vitro toxicity analysis of a supercritical fluid extract of Kava kava (Piper methysticum). J Ethnopharmacol. 2019;235:301-308.
42.	Biber A, Nöldner M, Schlegelmilch R. 'Development of a formulation of Kava-Kava extract through pharmacokinetic experiments in animals'. Naunyn Schmiedeberg's Arch Pharmacol. 1992;345.
43.	Singh Y, Devkota A. 'Aqueous kava extracts do not affect liver function tests in rats'. Planta medica. 2003;69(06):496-499.
44.	Robinson V, Bergfeld W, Belsito D, et al. 'Final report on the safety assessment of Piper methysticum leaf/root/stem extract and Piper methysticum root extract'. International journal of toxicology. 2009;28(6_suppl):175-188.
45.	Mathews JM, Etheridge AS, Valentine JL. PHARMACOKINETICS. AND DISPOSITION OF THE KAVALACTONE KAWAIN: INTERACTION WITH KAVA EXTRACT AND KAVALACTONES IN VIVO AND IN VITRO Drug Metab Dispos. 2005;33(10):1555-1563.
46.	Wang P, Zhu J, Shehu A, et al. 'Enzymes and Pathways of Kavain Bioactivation and Biotransformation'. Chemical research in toxicology. 2019;32(7):1335-1342.
47.	Fu S, Rowe A, Ramzan I. 'Kavalactone metabolism in the isolated perfused rat liver'. Phytotherapy Research. 2012;26(12):1813-1816.
48.	Rasmussen A, Scheline R, Solheim E, Hänsel R. 'Metabolism of some kava pyrones in the rat'. Xenobiotica. 1979;9(1):1-16.
49.	Narayanapillai SC, Leitzman P, O’Sullivan MG, A XCF, Kava B. Not Dihydromethysticin, Potentiate Acetaminophen-Induced Hepatotoxicity in C57BL/6 Mice. Chem Res Toxicol. 2014;27(10):1871-1876.
50.	Eldridge CSR, J M, J. Characterization of acute biliary hyperplasia in Fisher 344 Rats administered the Indole-3-Carbinol Analog, NSC-743380. Toxicology and Applied Pharmacology. 2014;281(3):303-309.
51.	Yamazaki Y, Hashida H, Arita A, Hamaguchi K, Shimura F. High dose of commercial products of kava (Piper methysticum) markedly enhanced hepatic cytochrome P450 1A1 mRNA expression with liver enlargement in rats. Food and Chemical Toxicology. 2008;46(12):3732-3738.
52.	Guo L, Li Q, Xia Q, Dial S, Chan P-C, Fu P. Analysis of Gene Expression Changes of Drug Metabolizing Enzymes in the Livers of F344 Rats Following Oral Treatment with Kava Extract. Food and Chemical Toxicology. 2009;47(2):433-442.
53.	Behl M, Nyska A, Chhabra RS. Liver toxicity and carcinogenicity in F344/N rats and B6C3F1 mice exposed to Kava Kava. Food and Chemical Toxicology. 2011;49(11):2820-2829.
54.	Lim STS, Dragull K, Tang CS, Bittenbender HC, Efird JT, Nerurkar PV. Effects of Kava Alkaloid, Pipermethystine, and Kavalactones on Oxidative Stress and Cytochrome P450 in F-344 Rats. Toxicological Sciences. 2007;97(1):214-221.
55.	Li X, Xu X, Ji T, et al. Dietary Feeding of Flavokawain A, a Kava Chalcone, Exhibits a Satisfactory Safety Profile and Its Association with Enhancement of Phase II Enzymes in Mice. Toxicology Reports. 2014;1:2-11.
56.	DiSilvestro RA, Zhang W, DiSilvestro DJ. Kava feeding in rats does not cause liver injury nor enhance galactosamine-induced hepatitis. Food and Chemical Toxicology. 2007;45(7):1293-1300.
57.	Hasan A, Mohammed SM, Rahman HS, Othman HH, Omer SH, Farasani A. The Sub-Acute Toxicity of Kavalactone in Rats: A Study of the Effect of Oral Doses and the Mechanism of Toxicity in Combination with Ethanol. Drug and Chemical Toxicology. 2022;May:1-9.
58.	Dunnick JK, Nyska A. The Toxicity and Pathology of Selected Dietary Herbal Medicines. Toxicol Pathol. 2013;41(2):374-386.
59.	Clayton NP, Yoshizawa K, Kissling GE, Burka LT, Chan P-C, Nyska A. Immunohistochemical Analysis of Expressions of Hepatic Cytochrome P450 in F344 Rats Following Oral Treatment with Kava Extract. Experimental and Toxicologic Pathology. 2007;58(4):223-236.
60.	Sorrentino L, Capasso A, Schmidt M. Safety of ethanolic kava extract: of a study of chronic toxicity in rats. Phytomedicine: International Journal of Phytotherapy & Phytopharmacology. 2006;13(8):542-550.
61.	Ferreira JV, Pierotte IC, Rodrigues FF, et al. Acute oral toxicity, antinociceptive and antimicrobial activities of kava dried extracts and synthetic kavain. Nat Prod Res. 2021;36(16):4221-4226.
62.	Noor NA. Anxiolytic Action and Safety of Kava: Effect on Rat Brain Acetylcholinesterase Activity and Some Serum Biochemical Parameters. In:2010.
63.	Whittaker P, Clarke JJ, San RHC. Evaluation of commercial kava extracts and kavalactone standards for mutagenicity and toxicity using the mammalian cell gene mutation assay in L5178Y mouse lymphoma cells. Food and Chemical Toxicology. 2008;46(1):168-174.
64.	Michael White C. Pharmacologic and Clinical Assessment of Kratom. American Journal of Health-System Pharmacy. 2018;75(5):261-267.
65.	Kanumuri SRR, Mamallapalli J, Nelson R, et al. Clinical pharmacokinetics of kavalactones after oral dosing of standardized kava extract in healthy volunteers. J Ethnopharmacol. 2022;297:115514.
66.	Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev. 2003(1):Cd003383.
67.	Ulbricht C, Basch E, Boon H, et al. Safety review of kava (Piper methysticum) by the Natural Standard Research Collaboration. Expert Opinion on Drug Safety. 2005;4(4):779-794.
68.	EMA (2016) Assessment report on Piper methysticum G. Forst., rhizoma (draft). Available at: https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-piper-methysticum-g-forst-rhizoma_en.pdf (Accessed: November 23 2021).
69.	Dufour J, Lin XL, Wang J, et al. The Safety of Multiple-Dose Liquid Blend Containing Kava and Kratom in Healthy Adults. Cureus. 2024;16(12):e75654.
70.	Ballotin VR, Bigarella LG, Brandao ABM, Balbinot RA, Balbinot SS, Soldera J. Herb-induced liver injury: Systematic review and meta-analysis. World J Clin Cases. 2021;9(20):5490-5513.
71.	Le TT, McGrath SR, Fasinu PS. Herb-drug Interactions in Neuropsychiatric Pharmacotherapy - A Review of Clinically Relevant Findings. Curr Neuropharmacol. 2022;20(9):1736-1751.
72.	Harbell MW, Dumitrascu C, Bettini L, Yu S, Thiele CM, Koyyalamudi V. Anesthetic Considerations for Patients on Psychotropic Drug Therapies. Neurol Int. 2021;13(4):640-658.
73.	Wang Y, Narayanapillai SC, Tessier KM, et al. The Impact of One-week Dietary Supplementation with Kava on Biomarkers of Tobacco Use and Nitrosamine-based Carcinogenesis Risk among Active SmokersKava-induced Reduction in Lung Cancer Risk and Tobacco Use. Cancer Prevention Research. 2020;13(5):483-492.
74.	Sarris J, Byrne GJ, Bousman CA, et al. 'Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study'. Aust N Z J Psychiatry. 2020;54(3):288-297.
75.	Clough AR, Bailie RS, Currie B. Liver function test abnormalities in users of aqueous kava extracts. J Toxicol Clin Toxicol. 2003;41(6):821-829.
76.	Clough AR, Jacups SP, Wang Z, et al. Health effects of kava use in an eastern Arnhem Land Aboriginal community. Intern Med J. 2003;33(8):336-340.
77.	Clough A. Enough! or too much. What is 'excessive' kava use in Arnhem Land? Drug Alcohol Rev. 2003;22(1):43-51.
78.	De Leo V, la Marca A, Morgante G, Lanzetta D, Florio P, Petraglia F. Evaluation of combining kava extract with hormone replacement therapy in the treatment of postmenopausal anxiety. Maturitas. 2001;39(2):185-188.
79.	Malsch U, Kieser M. Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines. Psychopharmacology (Berl). 2001;157(3):277-283.
80.	Cropley M, Cave Z, Ellis J, Middleton RW. Effect of kava and valerian on human physiological and psychological responses to mental stress assessed under laboratory conditions. Phytother Res. 2002;16(1):23-27.
81.	Connor KM, Davidson JR. A placebo-controlled study of Kava kava in generalized anxiety disorder. Int Clin Psychopharmacol. 2002;17(4):185-188.
82.	Boerner RJ, Sommer H, Berger W, Kuhn U, Schmidt U, Mannel M. Kava-Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder--an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients. Phytomedicine. 2003;10 Suppl 4:38-49.
83.	Gastpar M, Klimm HD. Treatment of anxiety, tension and restlessness states with Kava special extract WS 1490 in general practice: a randomized placebo-controlled double-blind multicenter trial. Phytomedicine. 2003;10(8):631-639.
84.	Cagnacci A, Arangino S, Renzi A, Zanni AL, Malmusi S, Volpe A. Kava-Kava administration reduces anxiety in perimenopausal women. Maturitas. 2003;44(2):103-109.
85.	Geier FP, Konstantinowicz T. Kava treatment in patients with anxiety. Phytother Res. 2004;18(4):297-300.
86.	Lehrl S. Clinical efficacy of kava extract WS 1490 in sleep disturbances associated with anxiety disorders. Results of a multicenter, randomized, placebo-controlled, double-blind clinical trial. J Affect Disord. 2004;78(2):101-110.
87.	Thompson R, Ruch W, Hasenöhrl RU. Enhanced cognitive performance and cheerful mood by standardized extracts of Piper methysticum (Kava-kava). Hum Psychopharmacol. 2004;19(4):243-250.
88.	Sarris J, Kavanagh DJ, Byrne G, Bone KM, Adams J, Deed G. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology (Berl). 2009;205(3):399-407.
89.	Sarris J, Kavanagh DJ, Deed G, Bone KM. St. John's wort and Kava in treating major depressive disorder with comorbid anxiety: a randomised double-blind placebo-controlled pilot trial. Hum Psychopharmacol. 2009;24(1):41-48.
90.	Sarris J, Stough C, Bousman CA, et al. Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2013;33(5):643-648.
91.	Sarris J, Byrne GJ, Bousman CA, et al. Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study. Aust N Z J Psychiatry. 2020;54(3):288-297.
92.	Wang Y, Narayanapillai SC, Tessier KM, et al. The Impact of One-week Dietary Supplementation with Kava on Biomarkers of Tobacco Use and Nitrosamine-based Carcinogenesis Risk among Active Smokers. Cancer Prev Res (Phila). 2020;13(5):483-492.
93.	Sarris J, Ravindran A, Yatham LN, et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. World J Biol Psychiatry. 2022;23(6):424-455.
94.	Savage K, Sarris J, Hughes M, et al. Neuroimaging Insights: Kava's (Piper methysticum) Effect on Dorsal Anterior Cingulate Cortex GABA in Generalized Anxiety Disorder. Nutrients. 2023;15(21).
95.	Witte S, Loew D, Gaus W. Meta-analysis of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders. Phytother Res. 2005;19(3):183-188.

